Clinical Trial Update: Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing ticagrelor vs placebo for reducing vaso-occlusive crises in pediatric sickle cell disease; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Sickle Cell Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-04-09